tiprankstipranks
The Fly

Evaxion Biotech completes dosing in phase 2 trial with EVX-01

Evaxion Biotech completes dosing in phase 2 trial with EVX-01

Evaxion Biotech (EVAX) has now completed the dosing of all 16 patients in its phase 2 trial with the company’s lead asset EVX-01. Designed with Evaxion’s AI-Immunology platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma. Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according to the protocol. Patients will continue to be monitored and data collected.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1